Pamela has held a variety of strategy, commercial and business development positions in small biotech companies, playing lead roles in transformative deals for each company. Pamela most recently served as the Chief Business Officer of Replimune where, from its inception, she was responsible for both corporate and business development and raised approximately $1 billion over 9 years. Before Replimune, she was Chief Business Officer at Ra Pharmaceuticals (acquired by UCB for ~$2.7B). As an early member of Ra’s senior management team, Pamela played a leadership role in strategy, helping Ra transform from a discovery platform to a clinical stage company and raising approximately $58 million in a Series B mezzanine funding round. Previously, she served as a business development consultant to Mariana Therapeutics, a peptide based radiopharma company, that was acquired by Novartis for $1B. Prior to Ra, she was VP of Business Development at Biovex and led the negotiation of the acquisition of the company by Amgen. Early in her career, she was a director at Bioduro based in Beijing, China and Vion Pharmaceuticals in New Haven, CT. Currently, Pamela sits on the board of directors of Accent Therapeutics and Kymera Therapeutics. Pamela earned a Ph.D. in pharmacology from Tufts University School of Medicine and a BA from Dartmouth College.
